In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

7-year clinical and angiographic results of endovascular treatment of patients with coronary artery diseases using second- and third-generation DES

Session Poster session 1

Speaker Associate Professor Daniil Maximkin

Congress : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session
  • FP Number : P888

Authors : Z Shugushev (Moscow,RU), D A Maximkin (Moscow,RU), R Goloshchapov-Aksenov (Moscow,RU), A Chepurnoy (Moscow,RU), A Faibushevich (Moscow,RU), N Sturov (Moscow,RU), A Nikitin (Moscow,RU)

Authors:
Z. Shugushev1 , D.A. Maximkin1 , R. Goloshchapov-Aksenov1 , A. Chepurnoy2 , A. Faibushevich1 , N. Sturov1 , A. Nikitin3 , 1RUDN University - Moscow - Russian Federation , 2Central Clinical Hospital of Russian Railways - Moscow - Russian Federation , 3Central Clinical Hospital Russian Academy of Science - Moscow - Russian Federation ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 198

Aims: To estimate the long-term results of effectiveness and safety second and third generations drug-eluting stents implantations in patients with coronary artery disease.

Methods and results: 367 patients were included in the study, which were randomized into 2 groups. Group I consisted of patients (n=192), which performed PCI with third generation biodegradable-polymer drug-eluting stents. Group II consisted patients (n=175), which performed PCI with second generation drug-eluting stents (Everolimus). Angiographic characteristics of patients:228 patients were 1–2 vessel diseases 86 patients were chronic total occlusions, 53 patients were bifurcation lesions. Inclusion criteria: stable angina (NYHA functional class II-III), myocardial ischemia confirmed stress tests. Exclusion criteria: LMCA diseases, acute coronary syndrome, multivessel diseases (SYNTAX score >32). 7-years results were followed in 183 patients from the Group I and 169 patients from the Group II. Primary endpoints: frequency of MACE (death, MI, repeat intervention). Secondary endpoints: restenosis and late stent thrombosis according to digital angiography, IVUS and OCT.

The survival rate in the late period was 96% in both groups. The frequency of MACE in both groups was 5.4 and 6.5%, respectively (p>0.05). The frequency of restenosis in Group I was 17.5%, in Group II - 8.3% (p<0.001). In this case, repeat revascularization (TLR) was needed in 8.7% of patients in Group I, and in 5.3% of patients in Group II (p<0.05). Stent thrombosis was diagnosed in 3 (1.6%) patients (2 in the RCA and 1 in the LCA) in Group I and 2 (1.2%) patients in Group II (in the LCA) (Ñ'>0.05). The frequency of intraoperative stent malposition according IVUS/OCT was in 187 patients. Post-dilatation by high pressure balloon catheter was performed in 73% of patients. Exercise tolerance after PCI in both groups was not significantly different and averaged 129,64±21,03 and 126,84±22,13Vt respectively (p=0.0423).

Conclusions: 7-years results of second and third generation's drug-eluting stents implantation did not show significant differences frequency of MACE. However, Biolomus-eluting stents showed poorer results on frequency of restenosis,as compared with Everolimus-eluting stents.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are